Ozempic for kids coming soon?

GLP-1 DRUGS FOR CHILDREN

Children as young as six are becoming the focus of new research into whether weight-loss medicines could play a role in treating childhood obesity, prompting widespread debate.

What possible benefits could come from using powerful appetite-regulating drugs at an early age, you may ask? I also have the same questions.

Well, pharmaceutical companies and paediatric specialists are currently investigating whether children with obesity could benefit from the new-age medical treatment.

Much of the research interest has centred on a group of medicines known as GLP-1 receptor agonists, found in popular products such as Ozempic.

These drugs mimic naturally occurring hormones involved in appetite control and blood sugar regulation, helping people feel fuller and reduce food intake.

The research has involved specialist paediatric obesity teams examining whether the medicine can ‘safely support weight management’ in this age group.

Boy, oh boy.

Where do these maniacs get off?

Eli Lilly is also studying newer medicines, including tirzepatide, in younger populations. Early research is examining ‘safety’ and how children’s bodies respond to the treatment.

The involvement of young children has raised significant questions.

Many are concerned about the limited information available on the effects of long-term treatment during important stages of growth and development.

A child starting medication at six years old could potentially take it for many years, making long-term safety a major consideration.

Others have questioned whether expanding access to weight-loss medicines could place too much emphasis on medication, rather than addressing wider causes of childhood obesity, including food environments, poverty, sleep patterns, and access to healthy lifestyles.

These are the real causes of obesity, in this hyper-processed and over-distracted world we live in, and they do not need to be treated with appetite-blocking drugs.

The grubby hands of Big Pharma are once again looking to be smeared all over our children – an idea I frankly think is beyond sickening.

The increasing trend of almost-instant weight loss as a result of next-generation medicines has already become a big problem in the adult world, and now they want to target children?

Just take a look at how things have played out so far with the grown populus.

Companies, as they always have, are playing you all for fools.

THE APPETITE ATTACK

From what once started as a fad among celebrities, has quickly taken over much of the Western world – as weight-loss drugs become the ‘go to’ for those looking to keep slim.

Semaglutide is the most common a GLP-1 receptor agonist that was originally developed to treat type 2 diabetes, but is now also widely used for chronic weight management.

And, as a result, used recreationally by people across the world.

Three semaglutide products (Ozempic, Wegovy and Rybelsus) are available, with use growing from primarily diabetes treatment to widespread obesity management.

They work by increasing insulin secretion when blood glucose is high, slowing stomach emptying, and reducing appetite, leading to lower blood glucose levels and weight loss.

Celebrities and major public figures played a major role in bringing semaglutide-based drugs such as Ozempic and Wegovy into mainstream conversation.

Around 2022, viewers noticed that several actors, comedians, reality TV stars, and entrepreneurs had lost weight rapidly – and they wanted a piece of the action.

This speculation made Ozempic a household name long before many people understood what the medication actually was – opening the doors for usage when it became commercially available across the world.

Standard Hollywood programming at its finest.

Today, around 420,000 Australians are using either semaglutide or tirzepatide (another GLP-1-type medicine) through private prescriptions.

This rise in popularity has also forced the food industry to change their approach.

As we know, Big Food has spent decades engineering products to keep people eating.

Now, with millions turning to weight-loss drugs like Ozempic, the industry faces a crisis: customers who simply don’t crave their products anymore.

Patients on popular weight loss drugs have reported losing interest in eating ultraprocessed junk, as thefoodindustry looks to combat this new emerging threat.

Big Pharma vs Big Food: The Battle for Your Appetite
RELATED VIDEO

So, what are they doing to navigate this shift?

Companies like Nestlé are introducing product lines such as Vital Pursuit, a new category of foods intended to be a “companion” for GLP-1 weight loss medication users.

Yes, I am not even joking.

They are now making food – essentially baby portions – for those who are taking these drugs to still be able to consume their products.

What a time to be alive.

Of course, like all drugs, there are many side effects with these weight-loss products.

Gastrointestinal problems are common side effects of using the drugs, while serious complications such as pancreatitis and gallbladder disease require medical attention.

For me, I couldn’t care less what grown adults do. You have the ability to make your own minds up about things – so if you want to be an idiot, I wish you well.

But my problem comes when they start targeting children, just like with vaccines, the education system, harmful algorithms, and every other avenue of psychological warfare.

How about you start actually fostering a world where children can actually be healthy, instead of a dystopian synthetic carbon-copy where they are made sick at every turn?

Perhaps that might actually solve the problems children are facing?

What say you? Be sure to leave a comment down below!

KEEP UP-TO-DATE

For more TOTT News:

Facebook — Facebook.com/TOTTNews

YouTube — YouTube.com/TOTTNews

Instagram — Instagram.com/TOTTNews

Twitter — Twitter.com/EthanTOTT

Rumble — Rumble.com/c/TOTTNews

Bitchute — Bitchute.com/TOTTNews

Gab — Gab.com/TOTTNews